751-3 Lovastatin and Probucol for the Prevention of Restenosls After Coronary Angioplasty

Abstract

We hypothesized that combination lipid lowering therapy (Lovastatin) and anti-oxidant (Probucol) therapy might reduce restenosis following coronary angioplasty(pTCA). To address this question, 239 patients (pts) were enrolled in a multi-center, randomized trial whereby 2 out of 3 pts received Lovastatin 20 mg bid and Probucol 500 mg bid in combination; l out of 3 pts was randomized to double placebo. Pts were treated in a blinded fashion for 6 months. Total cholesterol (154 vs 211), LDL (98 vs 141) and HDL (31 vs 42) were lower in treated compared with placebo patients. Serious adverse effects from the medications were not observed. EVENTS WITHIN 6 MONTHS Active (n = 163) Placebo (n = 76) Death 1(1%) 1(1%) Myocardial Infarction 3(2%) 1(1%) Repeat PTCA 51(31%) 22(29%) Bypass Surgery 7(4%) 3(4%) Quantitative coronary angiography was available in 147 lesions, the mean loss in luminal diameter was 27% ± 31% and 28% ± 34% in treated and placebo groups. Combination Lovastatin and Probucol: 1) reduced total cholesterol (27%). LDL (29%) and HDL (27%) levels, but 2) did not prevent restenosis or clinical events during the first six months post-angioplasty.